Matches in SemOpenAlex for { <https://semopenalex.org/work/W2965458093> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2965458093 abstract "Dasatinib is a potent tyrosine-kinase inhibitor which is used for chronic myeloid leukemia treatment. Pleural effusion is a frequent side effect in patients during dasatinib treatment. Pulmonary arterial hypertension is a rare and life-threatening adverse event of dasatinib. The relationship between dasatinib and autoimmune disorders is unclear, but there are reports of possible mechanisms that have triggered autoimmunity by dasatinib.A 53-year-old male was diagnosed with chronic myeloid leukemia and initiated imatinib mesylate as a treatment. Imatinib was changed to dasatinib as the patient was unresponsive in the first year of treatment. In the fourth year of dasatinib when chronic myeloid leukemia was in both hematological and cytogenetical remission, the patient presented with bilateral massive exudative pleural effusion. Echocardiography was consistent with pericardial effusion with right ventricle enlargement and normal left-side cardiac function. Pulmonary arterial hypertension was diagnosed with high systolic pulmonary arterial pressure. When he had fever and arthralgia, further investigation showed positivity of anti-nuclear antibodies (1/160 titer) and anti-RNP/Sm, which have high specificity for the diagnosis of Systemic Lupus Erythematosus (SLE).Dasatinib was discontinued and nilotinib was initiated. As the pleural effusion persisted despite diuretics and methylprednisolone, mycophenolate mofetil was initiated as a steroid-sparing immune-suppressive agent. The lupus-like symptoms disappeared, and antibodies became undetectable after dasatinib discontinuation. Pericardial effusion improved and pleural effusion did not relapse.Screening for auto-antibodies may be recommended for patients with a history or symptoms of autoimmune disease before starting dasatinib. All patients who develop pleural effusion while on dasatinib treatment should be investigated for antibodies for lupus." @default.
- W2965458093 created "2019-08-13" @default.
- W2965458093 creator A5004097738 @default.
- W2965458093 creator A5013494208 @default.
- W2965458093 creator A5041650351 @default.
- W2965458093 creator A5087693961 @default.
- W2965458093 date "2019-07-30" @default.
- W2965458093 modified "2023-10-16" @default.
- W2965458093 title "Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib" @default.
- W2965458093 cites W1589700409 @default.
- W2965458093 cites W1972656711 @default.
- W2965458093 cites W2006165265 @default.
- W2965458093 cites W2010109350 @default.
- W2965458093 cites W2051536771 @default.
- W2965458093 cites W2067978628 @default.
- W2965458093 cites W2073035156 @default.
- W2965458093 cites W2078783981 @default.
- W2965458093 cites W2082751900 @default.
- W2965458093 cites W2104125890 @default.
- W2965458093 cites W2107315055 @default.
- W2965458093 cites W2108810476 @default.
- W2965458093 cites W2126579741 @default.
- W2965458093 cites W2324415129 @default.
- W2965458093 cites W2397234997 @default.
- W2965458093 cites W2741643140 @default.
- W2965458093 doi "https://doi.org/10.1177/1078155219863469" @default.
- W2965458093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31359838" @default.
- W2965458093 hasPublicationYear "2019" @default.
- W2965458093 type Work @default.
- W2965458093 sameAs 2965458093 @default.
- W2965458093 citedByCount "3" @default.
- W2965458093 countsByYear W29654580932020 @default.
- W2965458093 countsByYear W29654580932021 @default.
- W2965458093 countsByYear W29654580932023 @default.
- W2965458093 crossrefType "journal-article" @default.
- W2965458093 hasAuthorship W2965458093A5004097738 @default.
- W2965458093 hasAuthorship W2965458093A5013494208 @default.
- W2965458093 hasAuthorship W2965458093A5041650351 @default.
- W2965458093 hasAuthorship W2965458093A5087693961 @default.
- W2965458093 hasConcept C126322002 @default.
- W2965458093 hasConcept C197934379 @default.
- W2965458093 hasConcept C2777583451 @default.
- W2965458093 hasConcept C2778715236 @default.
- W2965458093 hasConcept C2778729363 @default.
- W2965458093 hasConcept C2779536868 @default.
- W2965458093 hasConcept C2779634585 @default.
- W2965458093 hasConcept C2781175549 @default.
- W2965458093 hasConcept C3019892230 @default.
- W2965458093 hasConcept C71924100 @default.
- W2965458093 hasConcept C90924648 @default.
- W2965458093 hasConceptScore W2965458093C126322002 @default.
- W2965458093 hasConceptScore W2965458093C197934379 @default.
- W2965458093 hasConceptScore W2965458093C2777583451 @default.
- W2965458093 hasConceptScore W2965458093C2778715236 @default.
- W2965458093 hasConceptScore W2965458093C2778729363 @default.
- W2965458093 hasConceptScore W2965458093C2779536868 @default.
- W2965458093 hasConceptScore W2965458093C2779634585 @default.
- W2965458093 hasConceptScore W2965458093C2781175549 @default.
- W2965458093 hasConceptScore W2965458093C3019892230 @default.
- W2965458093 hasConceptScore W2965458093C71924100 @default.
- W2965458093 hasConceptScore W2965458093C90924648 @default.
- W2965458093 hasLocation W29654580931 @default.
- W2965458093 hasLocation W29654580932 @default.
- W2965458093 hasOpenAccess W2965458093 @default.
- W2965458093 hasPrimaryLocation W29654580931 @default.
- W2965458093 hasRelatedWork W11313001 @default.
- W2965458093 hasRelatedWork W15071589 @default.
- W2965458093 hasRelatedWork W15666944 @default.
- W2965458093 hasRelatedWork W16114088 @default.
- W2965458093 hasRelatedWork W17747543 @default.
- W2965458093 hasRelatedWork W17970610 @default.
- W2965458093 hasRelatedWork W18488647 @default.
- W2965458093 hasRelatedWork W18760892 @default.
- W2965458093 hasRelatedWork W2445216 @default.
- W2965458093 hasRelatedWork W5199437 @default.
- W2965458093 isParatext "false" @default.
- W2965458093 isRetracted "false" @default.
- W2965458093 magId "2965458093" @default.
- W2965458093 workType "article" @default.